Medpace Holdings, Inc. (MEDP) stock
MEDPNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 22, 2026Score 14/3042% above fair value
$653.09+4.89 (+0.75%)
Close on Nov 17, 2026Market cap $18.27BP/E 36.2Yield –
Medpace r&d expenses
Research and development expenses are spending on new products and technology.
No r&d expenses figures for Medpace
Medpace has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?